7 documents

Read All
21:43 , Dec 1, 2017 |  BC Week In Review  |  Company News

Neuropathic pain company Quartet ending operations

In a blog post, former Chairman of Quartet Medicine Inc. (Cambridge, Mass.) Bruce Booth said the biotech is winding down its operations. According to the post, Quartet found "some concerning and unexpected neurologic effects in...
Read More
23:42 , Nov 17, 2017 |  BC Extra  |  Company News

Neuropathic pain company Quartet ending operations

In a blog post, former Chairman of Quartet Medicine Inc. (Cambridge, Mass.) Bruce Booth said the biotech is winding down its operations. According to the post, Quartet found "some concerning and unexpected neurologic effects in...
Read More
08:00 , Nov 10, 2014 |  BioCentury  |  Emerging Company Profile

Quartet: Orchestrating pain relief

Quartet Medicine Inc. is developing inhibitors against two enzymes in the peripheral nervous system based on genetic findings that support a novel mechanism for ameliorating chronic neuropathic pain that could be complementary to centrally acting...
Read More
02:21 , Oct 24, 2014 |  BC Extra  |  Financial News

Quartet raises $17M series A

Analgesic developer Quartet Medicine (Cambridge, Mass.) raised $17 million in a series A round led by Atlas Venture. Novartis Venture Funds, Pfizer Venture Investment and Partners Innovation Fund also participated. Quartet is developing inhibitors of...
Read More
07:00 , Apr 22, 2010 |  BC Innovations  |  Targets & Mechanisms

Promoting pain resolution

Harvard Medical School researchers have shown that resolvins could help treat inflammatory pain without the side effects associated with opioids and COX-2 inhibitors. 1 The findings could open up a new indication for Resolvyx Pharmaceuticals...
Read More
07:00 , Jul 9, 2007 |  BioCentury  |  Emerging Company Profile

Solace: Comfort in (pain) research

Unlike typical biotech startups, which are founded by scientists-turned-entrepreneurs who have already chosen the company's founding assets, Solace Pharmaceuticals Inc. was formed by PureTech Ventures with the idea to pick development programs from a broad...
Read More
08:00 , Apr 1, 2002 |  BC Week In Review  |  Company News

Lund University other research news

Researchers published in the Proceedings of the National Academy of Sciences evidence that rAAV-TH and rAAV-GCH1 could be used as combination therapy to treat PD. In a rat model of PD, intrastriatal injection of rAAV-TH...
Read More